Chronic transfusion in sickle cell disease (SCD) remains the gold standard therapy for stroke prevention and for patients with severe disease despite adequate hydroxyurea treatment. The aim of our study was to assess the safety and efficacy of automated red blood cell exchange (aRBX) in patients with SCD previously treated with manual exchange transfusion (MET). Costs related to transfusion and chelation overtime were evaluated.
S
ickle cell disease (SCD) is a chronic disease associated with a number of acute complications, such as severe infection, vaso-occlusive pain episode, stroke, and splenic sequestration. [1] [2] [3] [4] Chronic complications include pulmonary hypertension, nephropathy, retinopathy, and osteonecrosis. 2, 4 Patients with SCD are at risk for earlier mortality. [5] [6] [7] Standard disease-modifying approaches for severely affected patients include hydroxyurea, chronic transfusion, and hematopoietic stem cell transplantation for patients having a human leukocyte antigen (HLA)-identical sibling. [8] [9] [10] [11] [12] [13] [14] [15] [16] Hydroxyurea is the only drug that has proven clinical relevant efficacy with significant decrease, for example, in vaso-occlusive crisis (VOC), acute chest syndrome (ACS), and transfusion requirement, [14] [15] [16] together with increase of basal hemoglobin level 17, 18 and survival improvement. 19, 20 However, chronic transfusion remains the gold standard therapy for primary and secondary stroke prevention despite promising results with hydroxyurea. [21] [22] [23] [24] [25] Chronic transfusion is also indicated for 1) patients with recurrent VOC or ACS despite optimal hydroxyurea treatment, [26] [27] [28] and 2) specific organ dysfunction. 26 Exchange transfusion is better than top-up transfusion, as it prevents iron overload 29, 30 and maintains hemoglobin S (HbS) level within target values. 30 Manual exchange transfusion (MET) is easy and does not require a specific device but is time consuming for the medical staff. Automated red blood cell exchange (aRBX) is a faster procedure with continuous control of fluid balance; it reduces iron overload but requires apheresis expertise and specialized equipment. It also increases the number of red blood cells (RBCs) needed for each procedure and might increase the risk of alloimmunization. 31 The aim of this study was to assess the safety and efficacy of aRBX in patients with SCD previously treated with MET in our center (Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium) and to evaluate the costs related to transfusion and chelation over procedure change. Our hypothesis was that the 10 patients who switched from MET to aRBCX would have improved iron burden and sufficient HbS suppression to ensure prevention of SCD complications at a similar cost.
MATERIALS AND METHODS
The aRBX program for patients with SCD was implemented in January 2012 in our institution. Patients on chronic transfusion program and previously treated with MET were eligible to switch to aRBX 1) if they have sufficient peripheral venous access to allow aRBX without the use of central venous line and 2) if they weighed 30 kg or more (to avoid the priming of the apheresis system). For chronically transfused patients, complete blood count, liver tests, ferritin, and antibody screening to RBC antigens are performed routinely before each transfusion (exchange procedure). Molecular RBC genotyping was not yet introduced in standard practice at the time of the study. In addition, our annual standard assessment for all patients with SCD includes, particularly, a 6-minute walk test, cardiac echography with measurement of tricuspid regurgitant jet velocity, and liver iron content (LIC) evaluation by T2* magnetic resonance imaging (MRI) when serum ferritin is above 500 mg/L. RBC units matched to the patient's phenotype were selected according to RH1, RH2, RH3, RH4, RH5, and KEL1 antigens (ABO, D, C, E, and KEL antigens). The Spectra Optia apheresis system was used. All procedures were performed using peripheral venous access. For both procedures, targets were 1) to obtain a preexchange HbS level less than 30% for stroke prevention and less than 50% for other indications, and 2) to maintain a hematocrit above 28%. For both MET and aRBX, exchanged volumes were calculated to maintain constant fluid balance. MET was prescribed considering Hb and preexchange HbS level. Practically the first exchange procedure for MET consisted in an OUT volume of 40 mL/kg compensated by 20 mL/kg of RBCs and 20 mL/kg of Hartmann in case of hematocrit of 25% or more. In case of hematocrit under 25%, the OUT volume of 40 mL/kg was compensated with 25 mL/kg of RBCs and 15 mL/kg of Hartmann. The subsequent exchange procedure was performed considering Hb and HbS level. For aRBX, the exchange volume was 1.53 the RBC volume and the targeted hematocrit was encoded as well as the anthropometric parameter of the patient. Data on biological values, duration of the procedure, intervals between procedures, as well as adverse events were recorded for the last 6 months on MET and compared to the data for aRBX up to 2 years after the first aRBX. The cost of RBCs, one day care facility, apheresis kit, and chelation were recorded. The overall costs of last year on MET and first and second year on aRBX were analyzed. The costs have been calculated on the basis of the one day care facility flat rates, the price of RBCs, and chelation (Table S1 , available as supporting information in the online version of this paper).
Statistics
Given the small size of this series of patients, we did not make any prior assumption about the expected difference in the outcomes, so there was no particular statistical power computation. Data are expressed as medians and range for quantitative variables. Statistical analyses were performed using software (Prism version 5, GraphPad Software, Inc. 
RESULTS
Ten patients on a chronic transfusion program (CTP) switched from MET to aRBX at a median age of 11.8 years (range, 9.7-16.8 years). Only one patient who weighed more than 30 kg was excluded from the switch due to her poor peripheral venous access. The characteristics of the patients are detailed in Table 1 . The median duration of MET before the start of aRBX was 1.9 years (range, 0.5-4.4 years). Indications for CTP were overt stroke (N 5 2 patients), suspicion of pulmonary hypertension with a tricuspid regurgitation velocity (TRV) 2.5 m/sec (N 5 2), recurrent VOC/ACS (N 5 5), and poorly tolerated severe anemia (N 5 1). All patients remained stable without any SCD-related event, except one child with previous history of stroke who presented with seizures without evidence of new stroke and for whom anticonvulsant therapy was resumed. Regarding chronic organ damage, one of the two patients with high TRV value reverted to normal TRV from 2.7 to 1.85 m/sec. Median TRV of our cohort was 1.95 m/sec (range, 1.3-2.7 m/sec) before MET, 2.08 m/sec (range, 1.2-2.67m/sec) at the start of aRBX and 2.0 m/sec (range, 1.3 -2.6 m/sec) after 2 years on aRBX (NS). The median age-standardized predicted values of the 6-minute walk distance at the start and after 2 years on aRBX was 87% (range, 67%-104%) and 89% (range, 70%-97%), respectively (NS). FEV 1 and FEV/FVC 1 remained stable over time. The evolution of the anthropometric data over time and the comparison of biological data and procedure parameters are detailed in Table 2 . Preexchange HbS level remained in the target values for all patients despite a significantly higher value on aRBX. No significant change in lactate dehydrogenase (LDH) occurred during aRBX when compared to MET. The duration of the exchange procedure decreased significantly and intervals between two aRBX were significantly longer than between two MET (p < 0.0001). During the second year on aRBX, the requirement for RBCs per procedure was significantly higher even when RBC volume was adjusted for weight (18.31 mL/kg per procedure on MET versus 29.84 mL/kg per procedure on aRBX). However, the requirement of RBCs per kilogram per year during the second year on aRBX was not significantly higher than on MET. The median ferritin level decreased significantly on aRBX (p < 0.001) (Fig. 1) . Five patients had LIC assessment (by T2* MRI) before the switch. Only two patients had iron overload with LIC of 130 mmol/g (Patient 1) and 250 mmol/g (Patient 9). After 2 years of aRBX, their LIC decreased to 20 mmol/g and 55 mmol/g, respectively. Patients 1 and 9 were on iron chelation (deferasirox) before starting aRBX but stopped the treatment after 10 and one aRBX procedures, respectively. No other patient required iron chelation at any time. Out of a total of 217 procedures of aRBX, eight adverse events (3.7%) required medical intervention and included transient hypotension (N 5 1), symptomatic hypocalcemia (N 5 4), transient headache (N 5 1), fever (N 5 1), and vomiting and abdominal pain (N 5 1). Other adverse events were related to either venous access or apheresis system but were not clinically relevant. Neither peripheral thrombosis nor infection has been reported. None of the patients developed allo-or autoimmunization during the follow-up.
The overall costs of the last year on MET and first and second years on aRBX are summarized in Table 3 . During the second year of treatment, the cost of aRBX was not significantly different from those on MET (103,270.02 e vs. 107,092.02 e) due to chelation stop in previously treated patients.
DISCUSSION
Chronic transfusion remains the gold standard treatment for primary and secondary stroke prevention. 23, 26 The goal of transfusion is to decrease the HbS level and to improve anemia. 30 The recommendations in chronically transfused children with SCD are to maintain an HbS level below 30% immediately prior to the next transfusion to avoid sickling and clinical events. 23, 30 However, in the literature, higher HbS levels prior the next transfusion are frequently reported (22%-84%), [32] [33] [34] [35] [36] showing the difficulty in complying with the recommendations. In our study, we observed a significant increase of preexchange HbS level after the switch (33.5% to 45%). However, the two patients who were exchanged for secondary stroke prevention remained around 30% after their switch to aRBX. For other indications, the less restrictive preexchange HbS level of less than 50% was reached for all the patients. Of interest, this higher residual HbS level did not jeopardize disease control, as shown by the absence of either SCD-related events or deterioration of organ dysfunction during the observation period. Our patients seem to have been better exchanged than those treated by manual procedure or by aRBX in other studies considering the higher preprocedure HbS level reported by many authors, ranging from 18% to 80% for MET and 28% to 84% for aRBX. [32] [33] [34] [35] [36] Moreover, and particularly on MET, our patients had much shorter intervals between procedures (28 days; range, 21-29 days) compared to other published data. Indeed, Koehl and colleagues have reported 35 days (range, 29-39 days) as the interval between transfusion sessions for both procedures. 37 In a recent study, Woods and coworkers reported that MET recipients achieved their goal of HbS in only 50% of visits (IQR 28.4%, 88.9%). 38 Regarding our patients while on aRBX, intervals were more comparable .02 e NS * p value between data using MET and after the second year using aRBX.
to those found in most publications. Woods reported a goal of HbS achievement in only 70% of visits. As previously published, aRBX is more effective than MET in decreasing HbS levels immediately after exchange transfusion but HbS levels before both procedures performed at the same interval were similar in those on MET or aRBX. 37, 38 Finally, in our experience on the 10 patients who switched from MET to aRBX, the shorter interval between procedures on MET can explain why in our cohort the median preprocedure HbS level was lower on MET than on aRBX. Using aRBX, we have been able to increase the interval between two procedures from 3 to 4 weeks for patients with prior stroke and from 4 to 6 weeks for other patients. The duration of the procedure has also been dramatically reduced. This gain of time combined with the absence of recurrent acute clinical events and stabilization of systemic organ involvement have contributed to decreasing the disease burden and need for treatment.
As inadequate venous access is an obstacle to longterm aRBX, and because our policy is to avoid the systematic use of a central venous line, we have selected for our aRBX program only patients who have an adequate peripheral access. Indeed, as is the case for other therapeutic apheresis, venous access is a major issue for patients, particularly for children requiring chronic exchange transfusion program. 39, 40 A long-term central venous line could be considered, but a double-lumen catheter with high flow is needed and may be associated with infections, thrombosis, and difficulties in blood withdrawal. 41 A permanent central line also requires appropriate regular care, represents a discomfort in daily life, and might be associated with a higher risk of thrombosis in patients with SCD. Billard and colleagues reported a good experience with a short-term femoral catheter insertion for each procedure, 42 but this approach in children requires sedation and the availability of an anesthetist team. Because most of the children will require a longterm exchange transfusion program and because the safety of a short-term femoral catheter still needs to be shown when performed over years, we have considered for our aRBX program only patients with suitable peripheral venous access. Some teams 35, 43 have reported good results with an arteriovenous fistula, but fistula revision is required for some patients. In addition, insertion of a temporary indwelling line prior to fistula formation is sometimes necessary, with the associated risk of line-related infection. In view of the limited experience with fistulas in children with SCD, we did not consider this approach. With use of aRBX, RBC requirement per procedure increased significantly the first and second years, but when calculated over a 1-year period and taking into account the patient weight, which increased over time, the RBC requirements expressed as units/kg/year increased significantly during the first year on aRBX but not the second year due to the increase of the interval between procedures. A dramatic decrease in ferritin level occurred on aRBX despite the absence of RBC requirements reduction. The unchanged LDH levels over time suggested a stable hemolytic rate and is not in favor of change in iron metabolism related to a reduced RBC turnover. One can argue that the removal of older RBCs could be optimized on aRBX compared to MET. Nevertheless, our policy with MET was to ensure a strict balance for globular mass as the volume transfused and removed were calculated taking into account the hematocrit of the patient and the hematocrit of the RBCs as well. The reason why ferritin decreases more with aRBX than with MET remains to be elucidated.
As aRBX requires more RBCs per procedure and as total unit exposure impacts alloimmunization, 31 the risk of alloimmunization might be increased. However, none of our patients developed alloimmunization using aRBX. Longer follow-up is needed to confirm the safety of the aRBX procedure concerning this immunological risk. Nevertheless, in a study of 45 patients followed from 1994 to 2010, Wahl and colleagues reported a significantly lower rate of alloimmunization on aRBX compared to a simple transfusion program, even if patients were exposed to more blood units. 44 Other reports have emphasized the importance of systematic phenotyping for RH1, RH2, RH3, RH4, RH5, and KEL1 antigens (performed before 2000 in our department) to improve the matching between the recipient and the blood donor. 30, 45, 46 These studies have demonstrated that this policy decreased the incidence of clinically significant immunization even for aRBX procedures. 30, 45, 46 As reported by Masera and colleagues and Koehl and coworkers, the cost of aRBX is not higher than the cost of MET. 37, 47 In our study, the comparison of RBC exchange procedure costs shows a clear benefit in favor of aRBX attributed to the fact that after 2 years no patient required chelation anymore. Regarding the comparison between the costs of aRBX and MET, only the costs of RBCs, one day clinic, and chelation have been taken into account in our model. Indeed, it was difficult to take into account the purchase of the machine as well as its depreciation expense, the costs related to the blood analyses (performed less frequently on aRBX than on MET) and the fact that the duration of bed occupancy was shorter for aRBX than for MET, therefore reducing nurses' workload. One should also consider that the costs of MET would have been increased anyway over time in growing children as RBC requirements increase with weight gain.
In conclusion, aRBX is useful and safe for patients with SCD who require a chronic exchange transfusion program. It is less time consuming for nurses and patients and improves iron overload. It can be performed successfully in children without any central line. In the context of the Belgian Health Care System, aRBX was not more expensive than MET. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's website. Table S1 . Detailed costs DEDEKEN ET AL.
